Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters
Venkatraman Siddharthan, Jinxin Miao, Arnaud J Van Wettere, Rong Li, Hua Wu, Eddie Sullivan, Jinan Jiao, Jay W. Hooper, David Safronetz, John D. Morrey, Justin G. Julander and Zhongde Wang | Utah Veterinary Diagnostics Laboratory; Department of Animal, Dairy, and Veterinary Sciences; Institute for Antiviral Research, and Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA; Department of Pathology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450066, China; SAB Biotherapeutics, Sioux Falls, SD 57104, USA; Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA; Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E, Canada | 2019 | Viruses, 11, 92; doi:10.3390/v11020092
Zika virus is a mosquito borne virus that causes Guillain-Barré syndrome, microcephaly and death in congenitally exposed fetuses. SAB Biotherapeutics has developed a transchromosomic bovine platform that produces large quantities of fully-human polyclonal antibodies (SAB-155) which is highly effective in treating ZIKV infection, both prophylactically and therapeutically. In this study levels of infection on non-treated and treated hamsters with the SAB-155 antibody where quantified by performing a RT-PCR on the MIC, where protection was conferred even 4.5 days post infection of the Zika virus.
Read More